Get started
Work

OA03.04 A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions

Year: 2023
Type: conference-abstract
DOI: 10.1016/j.jtho.2023.09.033
Authors: B. Han, C. Zhou, W. Zheng, L. Wu, Z. Ma, H. Wang, X. Yu, G. Ding, D. Ma, L. Nie, Z. Zhang, X. Dong, Y. Shang, K. Tang, W. Zhang, J.Y. Hsu, Y. Jiang, Q. Zhao
Institutions: Shanghai Jiao Tong University, Shanghai Chest Hospital, First Affiliated Hospital of Guangzhou Medical University, Sheng Jing Hospital, China Medical University, Hunan Cancer Hospital, Henan Cancer Hospital, Zhejiang Cancer Hospital, Anqing City Hospital, Affiliated Hospital of North Sichuan Medical College, Peking University First Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Affiliated Hospital of Hebei University, Hebei University, Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4388087214
Cites:
Cited by: 53
Related to: 10